2',3'-didehydro-3'-deoxy-3-methylthymidine | 142644-37-9

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 核苷和核苷酸类似物
• 英文名称: 2',3'-didehydro-3'-deoxy-3-methylthymidine
• 英文别名: 1-[(2R,5S)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]-3,5-dimethyl-pyrimidine-2,4-dione；1-[(2R,5S)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]-3,5-dimethylpyrimidine-2,4-dione
• CAS: 142644-37-9
• 化学式: C₁₁H₁₄N₂O₄
• 分子量: 238.243
• InChiKey: WRYFBXCZZWIKJD-DTWKUNHWSA-N

物化性质

• 沸点：
  394.8±52.0 °C(Predicted)
• 密度：
  1.337±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.6
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  70.1
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2',3'-didehydro-3'-deoxy-3-methylthymidine 在 磷酸三甲酯 、 三丁基焦磷酸铵 、 N,N'-羰基二咪唑 、 三氯氧磷 作用下， 反应 2.5h， 生成 3'-deoxy-2',3'-didehydrothymidine 5'-triphosphate
  参考文献：
  名称：

  Synthesis and Anti-human Immunodeficiency Virus Type 1(HIV-1) Activity of 3-Substituted Derivatives of 3'-Azido-3'-deoxythymidine (AZT), and Inhibition of HIV-1 Reverse Transcriptase by Their 5'-Triphosphates.

  摘要：

  通过 3'-azido-3'-deoxythymidine (1)、AZT 与 N, N-二甲基甲酰胺二烷基缩醛或烷基溴在碱存在下的反应，制备了各种 3 取代的 3'-azido-3'-deoxythymidine 类似物（2a-i），并评估了它们对人类免疫缺陷病毒 1 型（HIV-1）的活性。为了研究对 HIV-1 逆转录酶活性的抑制作用，还合成了相应的 5'-三磷酸类似物（9）。超出预期的是，一些 AZT 的 N3 衍生物在一定程度上保留了抗 HIV-1 的活性。在获得的化合物（2a-i）中，3-烯丙基-AZT（2e）对 MT-4 细胞中 HIV-1 的体外复制最有效，EC50 值为 0.9μM。然而，3-烯丙基-AZT 5'-三磷酸酯（9e）对 HIV-1 逆转录酶活性没有抑制作用。

  DOI：

  10.1248/cpb.40.920
• 作为产物：
  描述：

  beta-胸苷 在 吡啶 、 potassium tert-butylate 作用下， 反应 1.5h， 生成 2',3'-didehydro-3'-deoxy-3-methylthymidine
  参考文献：
  名称：

  A New Synthesis of 2′,3′-Didehydro-3′-deoxy-3-Alkylthymidine

  摘要：

  The preparation of 3-alkyl D4T derivatives has been carried out starting from the corresponding 5'-O-t-butyldimethylsilyl-3'-O-methanesulfonylthymidine 2 by way of deprotection-elimination and succesive alkylation reactions.

  DOI：

  10.1080/15257779508009490

文献信息

• Multi-API Loading Prodrugs
  申请人：Alkermes Pharma Ireland Limited

  公开号：US20160024011A1

  公开（公告）日：2016-01-28

  The present invention accomplishes this by having multiple molecules of parent drugs attached to carrier moieties and by extending the period during which the parent drug is released and absorbed after administration to the patient and providing a longer duration of action per dose than the parent drug itself. Prodrug conjugates are suitable for sustained delivery of heteroaryl, lactam-amide-, imide-, sulfonamide-, carbamate-, urea-, benzamide-, acylaniline-, cyclic amide- and tertiary amine-containing parent drugs that are substituted at the amide nitrogen or oxygen atom with labile aldehyde-linked prodrug moieties. The carrier groups of the prodrugs can be hydrophobic to reduce the polarity and solubility of the parent drug under physiological conditions.
• MULTI-API LOADING PRODRUGS
  申请人：Alkermes Pharma Ireland Limited

  公开号：US20180194732A1

  公开（公告）日：2018-07-12

  The present invention accomplishes this by having multiple molecules of parent drugs attached to carrier moieties and by extending the period during which the parent drug is released and absorbed after administration to the patient and providing a longer duration of action per dose than the parent drug itself. Prodrug conjugates are suitable for sustained delivery of heteroaryl, lactam- amide-, imide-, sulfonamide-, carbamate-, urea-, benzamide-, acylaniline-, cyclic amide- and tertiary amine-containing parent drugs that are substituted at the amide nitrogen or oxygen atom with labile aldehyde-linked prodrug moieties. The carrier groups of the prodrugs can be hydrophobic to reduce the polarity and solubility of the parent drug under physiological conditions.